Li Yin
Chief Technology OfficerMs. Li Yin serves as Chief Technology Officer of BioDlink International Company Limited since November 2023 and in charge of the Group’s ADC research centre and overseas business development. Ms. Yin has experience in chemistry and biopharmaceutical industries. Prior to joining the Group, between September 2014 and October 2023, Ms. Yin served as the head of bioconjugation development of WuXi Biologics Co., Ltd., a subsidiary of WuXi Biologics (Cayman) Inc. (Hong Kong Stock Exchange: 2269) and the head of new technology development and business support of WuXi XDC Co., Ltd., a subsidiary of WuXi XDC Cayman Inc. (Hong Kong Stock Exchange: 2268). Prior to that, Ms. Yin had successively worked for several biopharmaceutical companies in the United States, including Sigma Aldrich, DuPont-Merck Pharmaceuticals and Amgen. Ms. Yin received a bachelor’s degree in chemistry from Peking University in the PRC and a master’s degree in chemistry from Purdue University in the United States.
Positions
- Company NameBioDlink International Company LimitedStock Code01875PositionChief Technology OfficerColleagues
- JLJincai LiExecutive Chairman of the Board
- BXBen XiaoGroup Vice President of Finance & Investor Relations
- JBJian Bo ZhangChief Operating Officer
- WYWing Yat LuiJoint Company Secretary
- UGUlf GrawunderIndependent Non-executive Director
- XXXiaojie XiNon-executive Director
- XFXin FanIndependent Non-executive Director
- CHChaohong HuIndependent Non-executive Director
